Literature DB >> 17268529

Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma.

P Bonvini, E Zorzi, G Basso, A Rosolen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17268529     DOI： 10.1038/sj.leu.2404528

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  64 in total

Review 1.  Role of T cell-nuclear factor κB in transplantation.

Authors:  Luciana L Molinero; Maria-Luisa Alegre
Journal:  Transplant Rev (Orlando)       Date:  2011-11-08       Impact factor: 3.943

2.  An integrated network platform for contextual prioritization of drugs and pathways.

Authors:  Aldo Segura-Cabrera; Navneet Singh; Kakajan Komurov
Journal:  Mol Biosyst       Date:  2015-11

3.  The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF-κB positive feedback loop in peripheral T-cell lymphoma.

Authors:  Rebecca L Boddicker; N Sertac Kip; Xiaoming Xing; Yu Zeng; Zhi-Zhang Yang; Jeong-Heon Lee; Luciana L Almada; Sherine F Elsawa; Ryan A Knudson; Mark E Law; Rhett P Ketterling; Julie M Cunningham; Yanhong Wu; Matthew J Maurer; Megan M O'Byrne; James R Cerhan; Susan L Slager; Brian K Link; Julie C Porcher; Deanna M Grote; Diane F Jelinek; Ahmet Dogan; Stephen M Ansell; Martin E Fernandez-Zapico; Andrew L Feldman
Journal:  Blood       Date:  2015-04-01       Impact factor: 22.113

4.  Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma.

Authors:  Marc A Weniger; Edgar G Rizzatti; Patricia Pérez-Galán; Delong Liu; Qiuyan Wang; Peter J Munson; Nalini Raghavachari; Therese White; Megan M Tweito; Kieron Dunleavy; Yihong Ye; Wyndham H Wilson; Adrian Wiestner
Journal:  Clin Cancer Res       Date:  2011-06-28       Impact factor: 12.531

5.  ALK-negative anaplastic large cell lymphoma is sensitive to bortezomib through Noxa upregulation and release of Bax from Bcl-2.

Authors:  Saskia A G M Cillessen; Nathalie J Hijmering; Laura M Moesbergen; Wim Vos; Sue Ellen Verbrugge; Gerrit Jansen; Otto J Visser; Joost J Oudejans; Chris J L M Meijer
Journal:  Haematologica       Date:  2015-05-14       Impact factor: 9.941

Review 6.  Drug resistance in lung cancer.

Authors:  Manish Shanker; David Willcutts; Jack A Roth; Rajagopal Ramesh
Journal:  Lung Cancer (Auckl)       Date:  2010-05-08

7.  Bortezomib induces neuropathic pain through protein kinase C-mediated activation of presynaptic NMDA receptors in the spinal cord.

Authors:  Jing-Dun Xie; Shao-Rui Chen; Hong Chen; Hui-Lin Pan
Journal:  Neuropharmacology       Date:  2017-06-27       Impact factor: 5.250

Review 8.  Tumor cell survival pathways activated by photodynamic therapy: a molecular basis for pharmacological inhibition strategies.

Authors:  Mans Broekgaarden; Ruud Weijer; Thomas M van Gulik; Michael R Hamblin; Michal Heger
Journal:  Cancer Metastasis Rev       Date:  2015-12       Impact factor: 9.264

Review 9.  Bortezomib for the treatment of mantle cell lymphoma: an update.

Authors:  Bryan Hambley; Paolo F Caimi; Basem M William
Journal:  Ther Adv Hematol       Date:  2016-05-21

Review 10.  TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies.

Authors:  Peter A Holoch; Thomas S Griffith
Journal:  Eur J Pharmacol       Date:  2009-10-18       Impact factor: 4.432
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.